Related Experiment Video
Updated: Jul 3, 2026

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
Published on: August 10, 2017
Azacitidine and the beginnings of therapeutic epigenetic modulation
Kristen O'Dwyer1, Peter Maslak
1Memorial Sloan-Kettering Cancer Center, Leukemia Service, Department of Medicine, New York, 10021, USA.
Background:
Although originally developed as a cytarabine analog more than 40 years ago, azacitidine has been the subject of renewed interest in the era of cancer epigenetics.
Objective:
What is the history of the clinical development of azacitidine and how has it been applied successfully to the treatment of myelodysplastic syndromes (MDS)?
Methods:
We review the evolution of the use of azacitidine for the therapy of human disease and review the major studies that have laid the groundwork for its current clinical indication.
Conclusion:
The use of azacitidine has changed the approach to the treatment of MDS and has resulted in improved outcomes for patients.
More Related Videos
08:01A Two-Step Strategy that Combines Epigenetic Modification and Biomechanical Cues to Generate Mammalian Pluripotent Cells
Published on: August 29, 2020
09:56Epigenetic Engineering of K562 Cells: Dual-Vector Episomal Strategy for Stable Targeted DNA Methylation using dCas9-DNMT3A and -HDAC1 Fusion Proteins
Published on: October 31, 2025
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Epigenetic Regulation
Spreading of Chromatin Modifications
Writers
The writer is an enzyme that can...
Chromatin Modification in iPS Cells
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
Pharmacogenomics: Identification of New Drug Targets